The Non-Vascular Stents market size in Europe was around USD 285.63 million in 2024. It is expected to grow at a CAGR of 5.3% to reach USD 369.78 million by 2029. It captures 28% of the global market.
Rapid technological advancements, rising prevalence of cancer, and urolithiasis are major factors accelerating the European non-vascular stents market of the European region. Various advantages associated with smaller incisions, quick wound healing, less pain, and surgical scars further fuel market growth. Europe has a well-organized and advanced healthcare infrastructure is another significant factor contributing to the development of the market. The aging population diagnosing with chronic diseases such as lung cancer, pancreatic cancer, and colorectal cancer also boosts the European non-vascular stents market.
The high-cost pressure associated with these devices is majorly hampering the market. Unpredictable efficacy and strict regulatory framework are also hindering the market.
The European market is expected to hold a substantial market share during the forecast period due to the flourishing medical technology sector and the increasing prevalence of gastric cancer in the EU5 countries.
The UK non-vascular stents market was the leader in the European market in 2023. It is to the growing demand for minimally invasive procedures in the United Kingdom and quick recovery time that helps reduce the hospital stay of the patient associated with the non-vascular stents.
Germany is following the UK in leading the European non-vascular stents market and is expected to have fast growth in the market. Advance technologies like the development of radioactive and biodegradable stents, advanced stent designs, and change in material composition and new stent placement techniques help drive market growth.
Notable companies leading the Europe Non-Vascular Stents Market include CONMED Corporation, Taewoong Medical Co., Medtronic; C. R. Bard, Inc.; Boston Scientific Corporation; HOBBS MEDICAL, INC; Cook Medical; ELLA - CS, s.r.o.; Ltd.; Synchron Med Inc.; and Glaukos Corporation.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region